Trials / Recruiting
RecruitingNCT04212715
Prostate SABR With Intra-Prostatic SABR Boost
Prostate SABR With Intra-Prostatic SABR Boost: A Phase II Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- King Saud University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodule up to 50Gy. The pelvic lymph nodes and seminal vesicles will also receive 25 Gy in 5 weekly fractions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Pelvic SABR with intra-prostatic SABR | SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule |
Timeline
- Start date
- 2019-12-26
- Primary completion
- 2021-12-01
- Completion
- 2026-12-01
- First posted
- 2019-12-27
- Last updated
- 2020-01-02
Locations
1 site across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT04212715. Inclusion in this directory is not an endorsement.